Obstructive Sleep Apnea and Serotoninergic Signalling Pathway: Pathomechanism and Therapeutic Potential.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Sleep Apnea, Obstructive*/metabolism ; Sleep Apnea, Obstructive*/therapy ; Sleep Apnea, Obstructive*/complications ; Sleep Apnea, Obstructive*/physiopathology ; Serotonin*/metabolism ; Signal Transduction*; Humans ; Animals ; Receptors, Serotonin/metabolism

Obstructive Sleep Apnea (OSA) is a disorder characterized by repeated upper airway collapse during sleep, leading to apneas and/or hypopneas, with associated symptoms like intermittent hypoxia and sleep fragmentation. One of the agents contributing to OSA occurrence and development seems to be serotonin (5-HT). Currently, the research focuses on establishing and interlinking OSA pathogenesis and the severity of the disease on the molecular neurotransmitter omnipresent in the human body-serotonin, its pathway, products, receptors, drugs affecting the levels of serotonin, or genetic predisposition. The 5-HT system is associated with numerous physiological processes such as digestion, circulation, sleep, respiration, and muscle tone-all of which are considered factors promoting and influencing the course of OSA because of correlations with comorbid conditions. Comorbidities include obesity, physiological and behavioral disorders as well as cardiovascular diseases. Additionally, both serotonin imbalance and OSA are connected with psychiatric comorbidities, such as depression, anxiety, or cognitive dysfunction. Pharmacological agents that target 5-HT receptors have shown varying degrees of efficacy in reducing the Apnea-Hypopnea Index and improving OSA symptoms. The potential role of the 5-HT signaling pathway in modulating OSA provides a promising avenue for new therapeutic interventions that could accompany the primary treatment of OSA-continuous positive airway pressure. Thus, this review aims to elucidate the complex role of 5-HT and its regulatory mechanisms in OSA pathophysiology, evaluating its potential as a therapeutic target. We also summarize the relationship between 5-HT signaling and various physiological functions, as well as its correlations with comorbid conditions.

Nat Sci Sleep. 2021 Dec 24;13:2221-2238. (PMID: 34992481)
Exp Neurol. 2020 Apr;326:113165. (PMID: 31887304)
Biol Psychiatry. 2003 Nov 15;54(10):953-9. (PMID: 14625137)
J Clin Sleep Med. 2021 Mar 1;17(3):505-513. (PMID: 33118928)
Psychopharmacology (Berl). 1996 Sep;127(2):140-9. (PMID: 8888380)
J Clin Psychopharmacol. 1991 Feb;11(1):71-2. (PMID: 2040719)
Nutrients. 2023 Mar 17;15(6):. (PMID: 36986191)
J Neurophysiol. 2018 Jul 1;120(1):296-305. (PMID: 29617218)
Chest. 1999 May;115(5):1397-401. (PMID: 10334159)
J Cardiovasc Pharmacol. 1985;7 Suppl 7:S89-91. (PMID: 2412068)
Sleep Med. 2020 Aug;72:50-58. (PMID: 32544796)
Psychopharmacology (Berl). 1985;87(3):371-3. (PMID: 2867573)
Cardiovasc Drugs Ther. 1994 Dec;8(6):787-99. (PMID: 7742257)
Lancet. 1997 Jun 21;349(9068):1840-1. (PMID: 9269238)
Chem Commun (Camb). 2009 Jul 7;(25):3677-92. (PMID: 19557250)
Nat Sci Sleep. 2021 Feb 09;13:125-139. (PMID: 33603523)
Br J Pharmacol. 2018 Aug;175(16):3190-3199. (PMID: 29318587)
Neurochem Int. 2024 Feb;173:105672. (PMID: 38157886)
Sleep Med Rev. 2016 Aug;28:125-32. (PMID: 26694311)
Psychosomatics. 2004 Jul-Aug;45(4):325-35. (PMID: 15232047)
Chest. 2020 Feb;157(2):403-420. (PMID: 31539538)
FEBS Lett. 2015 Jul 8;589(15):1728-34. (PMID: 26070423)
Otolaryngol Head Neck Surg. 2018 Jul;159(1):194-202. (PMID: 29582703)
Eur J Neurosci. 2003 May;17(9):1896-906. (PMID: 12752789)
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10761-6. (PMID: 25002497)
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1659-67. (PMID: 10556137)
Sleep. 1998 Mar 15;21(2):131-6. (PMID: 9542796)
Am J Transl Res. 2017 Feb 15;9(2):546-557. (PMID: 28337282)
Respir Physiol Neurobiol. 2009 Aug 31;168(1-2):133-43. (PMID: 19481178)
Neurosci Lett. 2001 Jun 15;305(3):197-201. (PMID: 11403939)
Eur J Neurosci. 2021 Aug;54(4):5235-5244. (PMID: 33458858)
Am J Psychiatry. 1999 Aug;156(8):1170-6. (PMID: 10450256)
Best Pract Res Clin Rheumatol. 2015 Feb;29(1):147-55. (PMID: 26267008)
Brain Res. 1979 Mar 9;163(1):135-50. (PMID: 218676)
Int J Environ Res Public Health. 2022 Nov 22;19(23):. (PMID: 36497559)
Front Med (Lausanne). 2022 Apr 07;9:799792. (PMID: 35463036)
Behav Sleep Med. 2020 Jan-Feb;18(1):35-57. (PMID: 30453780)
Sleep Breath. 2015 Dec;19(4):1377-86. (PMID: 25758299)
Sleep. 2008 Jun;31(6):824-31. (PMID: 18548827)
Front Aging Neurosci. 2022 Jun 30;14:931536. (PMID: 35847660)
Sleep. 2001 Mar 15;24(2):155-60. (PMID: 11247051)
J Thorac Dis. 2016 Sep;8(9):E901-E917. (PMID: 27747026)
Crohns Colitis 360. 2022 Jul 06;4(3):otac026. (PMID: 36777429)
J Neurol. 2022 Oct;269(10):5356-5367. (PMID: 35608659)
J Clin Psychiatry. 2004;65 Suppl 16:4-7. (PMID: 15575797)
J Clin Med. 2019 Nov 02;8(11):. (PMID: 31684047)
Brain Res. 1997 Jan 30;747(1):156-9. (PMID: 9042541)
Am J Respir Med. 2003;2(1):21-9. (PMID: 14720019)
Am J Respir Crit Care Med. 2023 Nov 8;:. (PMID: 37939168)
J Sleep Res. 2012 Apr;21(2):195-203. (PMID: 21883593)
Science. 2003 Jul 18;301(5631):386-9. (PMID: 12869766)
Semin Oncol. 1992 Dec;19(6 Suppl 15):26-32. (PMID: 1485179)
Brain Res. 1976 Jan 23;101(3):569-75. (PMID: 1244990)
Mol Biol Rep. 2013 Nov;40(11):6223-31. (PMID: 24065538)
Int J Mol Sci. 2023 Mar 01;24(5):. (PMID: 36902195)
Nutrients. 2016 Jan 20;8(1):. (PMID: 26805875)
Obes Surg. 2011 Mar;21(3):316-27. (PMID: 19669842)
Biol Neonate. 1994;65(3-4):176-81. (PMID: 8038280)
Sci Adv. 2021 Dec 03;7(49):eabl3857. (PMID: 34851672)
Respir Physiol Neurobiol. 2002 Jul;131(1-2):65-77. (PMID: 12106996)
Arch Oral Biol. 2022 Jan;133:105315. (PMID: 34808513)
Sleep Med Clin. 2022 Mar;17(1):111-116. (PMID: 35216758)
Brain Res. 2006 Sep 19;1110(1):95-101. (PMID: 16876773)
Brain Res. 1990 Dec 10;535(2):281-7. (PMID: 2073606)
Transl Psychiatry. 2014 Nov 11;4:e479. (PMID: 25386956)
Neuropharmacology. 1999 Aug;38(8):1083-152. (PMID: 10462127)
Physiol Rep. 2022 May;10(10):e15245. (PMID: 35581741)
Respir Physiol Neurobiol. 2013 Apr 1;186(2):221-8. (PMID: 23454023)
Physiol Rev. 2010 Jan;90(1):47-112. (PMID: 20086074)
Sleep. 1999 Dec 15;22(8):1087-92. (PMID: 10617169)
Arch Gen Psychiatry. 1981 Jun;38(6):631-6. (PMID: 6166274)
PLoS One. 2008;3(10):e3301. (PMID: 18923670)
Am J Physiol Endocrinol Metab. 2022 Jul 1;323(1):E80-E091. (PMID: 35575233)
J Sleep Res. 2009 Mar;18(1):113-21. (PMID: 19250178)
Int J Geriatr Psychiatry. 2014 Mar;29(3):227-35. (PMID: 23754303)
J Neuroendocrinol. 2003 Apr;15(4):432-7. (PMID: 12622846)
Med Hypotheses. 2019 Dec;133:109399. (PMID: 31542611)
J Neurosci. 2018 Feb 21;38(8):1915-1925. (PMID: 29378860)
Chest. 2017 Nov;152(5):1070-1086. (PMID: 28527878)
Sleep. 2010 Jul;33(7):982-9. (PMID: 20614859)
Ann N Y Acad Sci. 1998 Dec 15;861:217-29. (PMID: 9928259)
Neurosci Biobehav Rev. 2017 Mar;74(Pt B):321-329. (PMID: 27397854)
Brain Res. 2004 Nov 26;1028(1):48-58. (PMID: 15518641)
N Engl J Med. 1982 Oct 21;307(17):1037-42. (PMID: 6750396)
Int Rev Psychiatry. 2005 Aug;17(4):277-82. (PMID: 16194800)
Am J Respir Crit Care Med. 2005 Nov 15;172(10):1338-47. (PMID: 16020803)
Chron Respir Dis. 2008;5(4):233-42. (PMID: 19029235)
Chem Rev. 2008 May;108(5):1614-41. (PMID: 18476671)
Am J Respir Crit Care Med. 1999 Dec;160(6):1824-9. (PMID: 10588592)
Pan Afr Med J. 2018 Jan 18;29:47. (PMID: 29875929)
J Gastroenterol Hepatol. 2023 Aug;38(8):1244-1251. (PMID: 37300443)
PLoS One. 2014 Jan 27;9(1):e86460. (PMID: 24475124)
Braz J Otorhinolaryngol. 2011 Jun;77(3):348-55. (PMID: 21739010)
Sleep Med Rev. 2013 Oct;17(5):321-9. (PMID: 23079209)
Arch Med Sci. 2017 Jun;13(4):851-863. (PMID: 28721154)
Crohns Colitis 360. 2023 Mar 17;5(2):otad016. (PMID: 36998248)
Ther Adv Neurol Disord. 2022 Nov 19;15:17562864221137505. (PMID: 36419869)
J Appl Physiol (1985). 1996 Aug;81(2):643-52. (PMID: 8872629)
Depress Anxiety. 2000;12 Suppl 1:2-19. (PMID: 11098410)
Pharmacol Biochem Behav. 1981 Jul;15(1):149-51. (PMID: 7197363)
Front Psychiatry. 2023 Nov 30;14:1289367. (PMID: 38098628)
Sci Rep. 2022 Aug 24;12(1):14453. (PMID: 36002579)
Neurobiol Aging. 2008 Dec;29(12):1830-8. (PMID: 17544547)
Brain Res. 2001 Apr 27;899(1-2):159-68. (PMID: 11311877)
Philos Trans R Soc Lond B Biol Sci. 2009 Sep 12;364(1529):2589-602. (PMID: 19651659)
Am J Respir Crit Care Med. 2021 Jan 15;203(2):161-162. (PMID: 32795248)
Int J Mol Sci. 2022 Oct 26;23(21):. (PMID: 36361741)
J Neurosci. 2008 Mar 5;28(10):2495-505. (PMID: 18322094)
Genet Test Mol Biomarkers. 2024 Apr;28(4):159-164. (PMID: 38657123)
Nature. 1995 Apr 6;374(6522):542-6. (PMID: 7700379)
Gastroenterology. 2007 Jan;132(1):397-414. (PMID: 17241888)
J Exp Biol. 2022 Jul 1;225(13):. (PMID: 35662341)
CNS Drug Rev. 2001 Spring;7(1):25-47. (PMID: 11420571)
Sci Rep. 2020 May 4;10(1):7497. (PMID: 32367059)
Int J Oral Maxillofac Surg. 2010 Dec;39(12):1149-59. (PMID: 21030210)
Case Rep Psychiatry. 2022 Nov 1;2022:2943059. (PMID: 36386061)
J Am Coll Cardiol. 2013 Aug 13;62(7):569-76. (PMID: 23770180)
Prim Care Companion J Clin Psychiatry. 2000 Apr;2(2):49-54. (PMID: 15014583)
Arch Int Pharmacodyn Ther. 1981 Dec;254(2):282-92. (PMID: 7337501)
Mol Brain. 2017 Jun 24;10(1):28. (PMID: 28646910)
Am J Respir Crit Care Med. 2004 Feb 1;169(3):348-53. (PMID: 14551167)
Pflugers Arch. 1998 Mar;435(4):485-94. (PMID: 9446695)
Annu Rev Med. 2009;60:355-66. (PMID: 19630576)
Brain Sci. 2023 Aug 12;13(8):. (PMID: 37626553)
Circulation. 2021 Jul 20;144(3):e56-e67. (PMID: 34148375)
Tunis Med. 2022 juillet;100(7):525-533. (PMID: 36571741)
Psychopharmacol Bull. 2016 Mar 1;46(1):77-104. (PMID: 27738376)
Chest. 2015 Jan;147(1):266-274. (PMID: 25560865)
J Res Med Sci. 2014 Mar;19(3):205-10. (PMID: 24949026)
Chest. 1991 Aug;100(2):416-21. (PMID: 1864117)
Brain Res. 2012 Jun 21;1461:111-8. (PMID: 22608068)
J Clin Psychiatry. 1988 Aug;49 Suppl:40-5. (PMID: 3045112)
Ann Am Thorac Soc. 2015 May;12(5):758-64. (PMID: 25719754)
Respirology. 2017 Nov;22(8):1500-1507. (PMID: 28901030)
Transl Neurosci. 2016 May 9;7(1):35-49. (PMID: 28123820)
Biomedicines. 2022 Jul 19;10(7):. (PMID: 35885049)
Physiol Behav. 2020 Mar 1;215:112788. (PMID: 31863855)
Int Clin Psychopharmacol. 2016 Nov;31(6):347-52. (PMID: 27384739)
Int J Mol Sci. 2020 May 15;21(10):. (PMID: 32429111)
J Neurophysiol. 2018 Jul 1;120(1):321-329. (PMID: 29617215)
Arch Ital Biol. 1979 Jan;117(1):1-12. (PMID: 45299)
J Cell Mol Med. 2019 Apr;23(4):2324-2332. (PMID: 30734486)
Sleep Disord. 2017;2017:6768323. (PMID: 29057124)

SKN/SP/571907/2023 Ministry of Education and Science, Poland

Keywords: SERT; obstructive sleep apnea; serotonin; sleep disruption

333DO1RDJY (Serotonin)
0 (Receptors, Serotonin)

Date Created: 20240914 Date Completed: 20240914 Latest Revision: 20240916

20240916

PMC11395478

10.3390/ijms25179427

39273373